Compare Boston Scientific Corporation (BSX) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Skyworks Solutions Inc — how do they compare? Boston Scientific Corporation trades at $51.55 (market cap $74.19B), while Skyworks Solutions Inc trades at $69.35 (market cap $10.28B). The key difference: Boston Scientific Corporation is far larger — about 7.2× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SWKS | |
|---|---|---|
Market Cap | $74.19B | $10.28B |
Sector | Health | Technology |
52-Week High | $108.14 | $83.40 |
52-Week Low | $42.63 | $52.50 |
Enterprise Value | $86.27B | $10.16B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
Skyworks Solutions (SWKS) trades at $69.82, up 1.5% today, with a bullish technical signal and strong recent earnings beats. The company reported Q3 2026 EPS of $1.08, exceeding expectations, driven by broad markets and AI data center growth. However, revenue and net income have trended downward from 2022 peaks. Analyst consensus is a Buy (58.34%), with a $66.00 price target, though the current price exceeds this. The pending Qorvo combination is a key strategic focus.
The outlook is mixed; solid execution and the Qorvo deal offer long-term potential, but near-term revenue contraction, margin pressure, and a recent SEC investigation pose risks. The stock's valuation appears full relative to earnings growth, suggesting cautious optimism is warranted amid integration uncertainties and macroeconomic headwinds affecting the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
